Loading...

Trump to Require Government to Buy American When It Comes to ‘Essential’ Drugs

August 6, 2020 by Dan McCue
Trump to Require Government to Buy American When It Comes to ‘Essential’ Drugs
President Donald Trump meets with Arizona Gov. Doug Ducey in the Oval Office of the White House in Washington, Wednesday, Aug. 5, 2020. (AP Photo/Andrew Harnik)

WASHINGTON – President Donald Trump signed an executive order Thursday requiring the federal government to buy “essential” drugs from U.S. companies, a White House trade advisor said.

“If we’ve learned anything from the China virus pandemic, it is that we are dangerously over-dependent on foreign nations for our essential medicines, for medical supplies like masks, gloves, goggles and medical equipment like ventilators,” Peter Navarro said during a conference call with reporters Thursday morning.

The president is expected to sign the order during a trip to Ohio, during which he is scheduled to deliver remarks on “economic prosperity” in Cleveland, before visiting a Whirlpool Corporation manufacturing plant in Clyde.

The order’s “buy American” provision requires the federal government to develop a list of “essential” medicines, and then requires the Defense Department, the Department of Health and Human Services, and the Department of Veterans Affairs to purchase U.S.-made versions of those drugs.

The World Health Organization already has such a list, but Navarro said more drugs are on that list than the U.S. will ever need.

The White House said the hope is that establishing a “basic level” of demand, will inspire further manufacturing investment in the U.S.

The order will also remove some of the regulations on U.S. pharmaceutical manufacturers and accelerate Food and Drug Administration and Environmental Protection Agency approval of drug manufacturing facilities in a bid to make domestic production easier, Navarro said.

Another component will combat the importation of counterfeit medicines on e-commerce platforms, he said.

“At a time when our nation’s priority should be to beat COVID-19, President Trump today signed yet another executive order that creates even more barriers to ongoing biopharmaceutical manufacturing and innovation,” said Stephen J. Ubl, president and CEO of PhRMA, which represents the country’s leading biopharmaceutical researchers and biotechnology companies.

“Companies are working around the clock to research and develop treatments and a vaccine for COVID-19. At the same time, they are working to ensure they have the capacity to manufacture the treatments and vaccines once approved so that every patient that needs them has access to them,” Ubl continued. “These efforts are all hands on deck for the biopharmaceutical industry but each executive order issued by the administration adds another roadblock, making it harder to fight this pandemic.”

The order comes as the U.S. continues to be in the grips of the coronavirus, which has infected nearly 5 million Americans and killed at least 158,268, according to Johns Hopkins University.

Early on in the outbreak, the federal government warned consumers of disruptions in the medical supply chain because so many products were made in China and elsewhere, and for a time there were dramatic shortages of some medicines, key medicine ingredients, face masks, and gloves.

Now, the administration is becoming the problem, PhRMA’s Ubl said.

“The administration is forcing biopharmaceutical companies to shift their critical attention and resources away from COVID-19 work to focus on making substantial changes to their business models necessary to comply with this and other recent executive orders,” he said. “Increasing U.S. manufacturing of medicines is a laudable goal, but it cannot happen overnight and should not come at the expense of medical innovation or Americans’ access to the medicines they need.

“The recent executive orders also contradict and undermine each other, creating chaos in an industry that is on the frontlines of fighting COVID-19,” Ubl continued. “With today’s ‘Buy American’ executive order, the administration effectively is taking the unprecedented step of mandating manufacturing of medicines in the United States. Yet at the same time, through the ‘most favored nation’ executive order, the administration is creating a huge disincentive to invest in U.S. biopharmaceutical research and manufacturing.

“Together, the result is less investment in U.S. innovation and the potential for major long-term supply chain disruptions – the opposite of what America needs right now. None of these executive orders will help patients access or afford their medicines,” he said.

“The ‘Buy American’ executive order could disrupt the global pharmaceutical supply chain, jeopardizing our ability to respond to the current crisis and potentially leading to major long-term supply chain disruptions, including shortages. Rather than government mandates, we should look for policies that enable more domestic manufacturing without putting the stability of pharmaceutical supply chains at risk,” Ubl concluded.

In The News

Health

Voting

Prescription Drugs

Pfizer Buying Spree Continues With $5.4B Hematology Deal

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of... Read More

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic. Pfizer said Monday that the acquisition will boost its capabilities in rare hematology. Global Therapeutics makes Oxybryta tablets... Read More

Over-the-Counter Birth Control? Drugmaker Seeks FDA Approval

WASHINGTON (AP) — For the first time, a pharmaceutical company has asked for permission to sell a birth control pill... Read More

WASHINGTON (AP) — For the first time, a pharmaceutical company has asked for permission to sell a birth control pill over the counter in the U.S. HRA Pharma’s application on Monday sets up a high-stakes decision for health regulators amid legal and political battles over women’s... Read More

July 8, 2022
by Natalie McCormick
Overturning Roe Has Birth Control and Emergency Contraceptives in High Demand

WASHINGTON — In the wake of the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization, which overturned Roe... Read More

WASHINGTON — In the wake of the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization, which overturned Roe v. Wade, demand for various forms of contraceptives, including the so-called morning-after pill, and long-lasting forms of birth control, has surged.  Doctors, women’s health clinics and... Read More

July 5, 2022
by Tom Ramstack
Drug Distributors Win Lawsuit Accusing Them of Opioid Abuse

CABELL COUNTY, W.Va. — A federal judge in West Virginia on Monday ruled in favor of drug distribution companies accused... Read More

CABELL COUNTY, W.Va. — A federal judge in West Virginia on Monday ruled in favor of drug distribution companies accused in a lawsuit of creating a public nuisance by distributing opioids that kill thousands of Americans each year. The judge said his ruling is "not based... Read More

April 27, 2022
by Tom Ramstack
Lawmakers Say Consulting Firm Marketing Contributed to Half-Million Opioid Deaths

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the... Read More

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the opioid epidemic that has killed more than a half-million Americans. A McKinsey & Co. official admitted to earning at least $86 million for helping pharmaceutical companies... Read More

April 19, 2022
by Dan McCue
Supreme Court Seeks Solicitor General Input on Biologic Drug Patents

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent... Read More

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent case the outcome of which could ultimately be worth billions of dollars. The case, Amgen v. Sanofi, emanates from the U.S. District Court for the Federal... Read More

News From The Well